BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Amiot A, Hulin A, Belhassan M, Andre C, Gagniere C, Le Baleur Y, Farcet JP, Delchier JC, Hüe S. Therapeutic drug monitoring is predictive of loss of response after de-escalation of infliximab therapy in patients with inflammatory bowel disease in clinical remission. Clin Res Hepatol Gastroenterol. 2016;40:90-98. [PMID: 26138132 DOI: 10.1016/j.clinre.2015.05.019] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
Number Citing Articles
1 Sanchez-Hernandez JG, Rebollo N, Munoz F, Martin-Suarez A, Calvo MV. Therapeutic drug monitoring of tumour necrosis factor inhibitors in the management of chronic inflammatory diseases. Ann Clin Biochem 2019;56:28-41. [PMID: 29807436 DOI: 10.1177/0004563218782286] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
2 Papamichael K, Cheifetz AS. Editorial: therapeutic de-escalation of anti-tumour necrosis factor therapy - is less enough? Aliment Pharmacol Ther 2017;45:1265-6. [PMID: 28370052 DOI: 10.1111/apt.14000] [Reference Citation Analysis]
3 Cheon JH. Understanding the complications of anti-tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease: Biologics therapy in East Asia. Journal of Gastroenterology and Hepatology 2017;32:769-77. [DOI: 10.1111/jgh.13612] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
4 Nasser Y, Labetoulle R, Harzallah I, Berger A, Roblin X, Paul S. Comparison of Point-of-Care and Classical Immunoassays for the Monitoring Infliximab and Antibodies Against Infliximab in IBD. Dig Dis Sci 2018;63:2714-21. [DOI: 10.1007/s10620-018-5144-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
5 Einarson TR, Bereza BG, Ying Lee X, Lelli F. Dose escalation of biologics in Crohn’s disease: critical review of observational studies. Current Medical Research and Opinion 2017;33:1433-49. [DOI: 10.1080/03007995.2017.1335001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
6 Lamb CA, Saifuddin A, Powell N, Rieder F. The Future of Precision Medicine to Predict Outcomes and Control Tissue Remodeling in Inflammatory Bowel Disease. Gastroenterology 2022;162:1525-42. [PMID: 34995532 DOI: 10.1053/j.gastro.2021.09.077] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Petitcollin A, Brochard C, Siproudhis L, Tron C, Verdier M, Lemaitre F, Lucidarme C, Bouguen G, Bellissant É. Pharmacokinetic Parameters of Infliximab Influence the Rate of Relapse After De‐Escalation in Adults With Inflammatory Bowel Diseases. Clin Pharmacol Ther 2019;106:605-15. [DOI: 10.1002/cpt.1429] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 7.3] [Reference Citation Analysis]
8 Tighe D, McNamara D. Clinical impact of immunomonitoring in the treatment of inflammatory bowel disease. World J Gastroenterol 2017; 23(3): 414-425 [PMID: 28210077 DOI: 10.3748/wjg.v23.i3.414] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
9 Mitrev N, Leong RW. Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease. Expert Opin Drug Saf 2017;16:303-17. [PMID: 27922765 DOI: 10.1080/14740338.2017.1269169] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
10 Grossberg LB, Cheifetz AS, Papamichael K. Therapeutic Drug Monitoring of Biologics in Crohn’s Disease. Gastroenterology Clinics of North America 2022. [DOI: 10.1016/j.gtc.2021.12.007] [Reference Citation Analysis]
11 Landemaine A, Petitcollin A, Brochard C, Miard C, Dewitte M, Le Balc'h E, Grainville T, Bellissant E, Siproudhis L, Bouguen G. Cumulative Exposure to Infliximab, But Not Trough Concentrations, Correlates With Rate of Infection. Clin Gastroenterol Hepatol 2021;19:288-295.e4. [PMID: 32200087 DOI: 10.1016/j.cgh.2020.03.018] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
12 Annese V, Nathwani R, Alkhatry M, Al-Rifai A, Al Awadhi S, Georgopoulos F, Jazzar AN, Khassouan AM, Koutoubi Z, Taha MS, Limdi JK. Optimizing biologic therapy in inflammatory bowel disease: a Delphi consensus in the United Arab Emirates. Therap Adv Gastroenterol 2021;14:17562848211065329. [PMID: 34987611 DOI: 10.1177/17562848211065329] [Reference Citation Analysis]
13 Papamichael K, Cheifetz AS, Melmed GY, Irving PM, Vande Casteele N, Kozuch PL, Raffals LE, Baidoo L, Bressler B, Devlin SM, Jones J, Kaplan GG, Sparrow MP, Velayos FS, Ullman T, Siegel CA. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2019;17:1655-1668.e3. [PMID: 30928454 DOI: 10.1016/j.cgh.2019.03.037] [Cited by in Crossref: 87] [Cited by in F6Publishing: 65] [Article Influence: 29.0] [Reference Citation Analysis]
14 Sheasgreen C, Nguyen GC. The Evolving Evidence for Therapeutic Drug Monitoring of Monoclonal Antibodies in Inflammatory Bowel Disease. Curr Gastroenterol Rep 2017;19:19. [PMID: 28397129 DOI: 10.1007/s11894-017-0559-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
15 Targownik LE, Benchimol EI, Bernstein CN, Singh H, Tennakoon A, Zubieta AA, Coward S, Jones J, Kaplan GG, Kuenzig ME, Murthy SK, Nguyen GC, Peña-Sánchez JN. Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications. J Crohns Colitis 2020;14:1354-63. [PMID: 32648579 DOI: 10.1093/ecco-jcc/jjaa050] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
16 Cheifetz AS, Abreu MT, Afif W, Cross RK, Dubinsky MC, Loftus EV Jr, Osterman MT, Saroufim A, Siegel CA, Yarur AJ, Melmed GY, Papamichael K. A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease. Am J Gastroenterol 2021. [PMID: 34388143 DOI: 10.14309/ajg.0000000000001396] [Reference Citation Analysis]
17 Danese S, Fiorino G, Peyrin-Biroulet L. Early intervention in Crohn's disease: towards disease modification trials. Gut 2017;66:2179-87. [PMID: 28874419 DOI: 10.1136/gutjnl-2017-314519] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 9.2] [Reference Citation Analysis]
18 Lucidarme C, Petitcollin A, Brochard C, Siproudhis L, Dewitte M, Landemaine A, Bellissant E, Bouguen G. Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring. Aliment Pharmacol Ther 2019;49:147-54. [DOI: 10.1111/apt.15046] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 6.5] [Reference Citation Analysis]
19 Papamichael K, Osterman MT, Siegel CA, Melmed GY, Dubinsky MC, Colombel JF, Hanauer SB, Cheifetz AS. Using Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: From an Old Concept to a Future Standard of Care? Gastroenterology 2018;154:1201-2. [PMID: 29432749 DOI: 10.1053/j.gastro.2018.01.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
20 Sahu P, Vuyyuru SK, Kante B, Agarwal A, Sharma R, Das P, Panwar R, Jain S, Bopanna S, Makharia G, Kedia S, Ahuja V. Relapse rate following withdrawal of anti-TNF therapy in patients with inflammatory bowel disease: A real-life cohort from northern India. Indian J Gastroenterol 2020;39:388-97. [PMID: 32880844 DOI: 10.1007/s12664-020-01043-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
21 Boyapati RK, Torres J, Palmela C, Parker CE, Silverberg OM, Upadhyaya SD, Nguyen TM, Colombel JF. Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease. Cochrane Database Syst Rev 2018;5:CD012540. [PMID: 29756637 DOI: 10.1002/14651858.CD012540.pub2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
22 Ben-shatach Z, Ziv-baran T, Fudim E, Yavzori M, Picard O, Levartovsky A, Selinger L, Weiss B, Kopylov U, Eliakim R, Ungar B. Delaying an infliximab infusion by more than 3 days is associated with a significant reduction in trough levels but not with clinical worsening. Therap Adv Gastroenterol 2022;15:175628482210833. [DOI: 10.1177/17562848221083395] [Reference Citation Analysis]
23 East JE, Boyapati RK, Torres J, Parker CE, MacDonald JK, Chande N, Feagan BG. Controversies in Inflammatory Bowel Disease: Exploring Clinical Dilemmas Using Cochrane Reviews. Inflamm Bowel Dis 2019;25:472-8. [PMID: 30789982 DOI: 10.1093/ibd/izy268] [Reference Citation Analysis]
24 Rabbi MF, Eissa N, Munyaka PM, Kermarrec L, Elgazzar O, Khafipour E, Bernstein CN, Ghia JE. Reactivation of Intestinal Inflammation Is Suppressed by Catestatin in a Murine Model of Colitis via M1 Macrophages and Not the Gut Microbiota. Front Immunol 2017;8:985. [PMID: 28871257 DOI: 10.3389/fimmu.2017.00985] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 4.4] [Reference Citation Analysis]